GE HealthCare in reported talks to buy radiopharmaceutical firm Sofie Biosciences for $1B

GE HealthCare is in talks to acquire radiopharmaceutical manufacturer Sofie Biosciences for $1 billion; the Financial Times reports a deal could be announced within a week. Sofie runs 15 U.S. sites and manufactured over 567,000 doses for partners and customers.

• The deal is not final, and both GE HealthCare and Sofie declined to comment on the record.
• Sofie has contract manufacturing and theranostic intellectual property, plus a pancreatic cancer diagnostic agent in development with first patient dosing in February.
• This would be GE HealthCare's second billion-dollar acquisition since its 2023 spin-off, following its $2.3 billion Intelerad deal.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.